<DOC>
	<DOCNO>NCT01199224</DOCNO>
	<brief_summary>Compare bioavailability three veliparib formulation subject solid tumor .</brief_summary>
	<brief_title>To Determine Food Effect Bioavailability Three Formulations Veliparib Subjects With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Veliparib</mesh_term>
	<criteria>1 . Subjects cytologically/histologically confirm solid tumor either relapse refractory standard therapy know effective therapy . 2 . In opinion Investigator , life expectancy 12 week great . 3 . Subjects know brain metastasis must clinically control neurologic symptom , define surgical excision and/or radiation therapy follow 21 day stable neurologic function evidence central nervous system ( CNS ) disease progression determine compute tomography ( CT ) scan magnetic resonance imaging ( MRI ) within 21 day prior first dose study drug . 4 . Subject Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 . 5 . Subject must adequate bone marrow , renal hepatic function per local laboratory reference range . 1 . The subject unable swallow capsule nausea vomit . 2 . Female subject pregnant breastfeeding . 3 . Subject history active medical condition ( ) affect absorption motility ( e.g. , Crohn 's disease , celiac disease , gastroparesis , short bowel syndrome ) . 4 . History gastric surgery , vagotomy , bowel resection ( except leave hemicolectomy ) surgical procedure might interfere gastrointestinal motility , potentiometric hydrogen ion concentration ( pH ) absorption . 5 . Subject exhibit evidence clinically significant uncontrolled condition ( ) include , limited : Known seizure disorder uncontrolled past month Active uncontrolled infection Unstable angina pectoris cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>veliparib</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
</DOC>